Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab or Sotrovimab on Persistently High Viral Load in Patients with Mild-to-Moderate COVID-19: A Randomized, Phase  2 BLAZE-4 Trial

ConclusionThe study demonstrated that a significantly lower proportion of patients with mild-to-moderate COVID-19 treated with BAM or BAM  + (ETE or sotrovimab) experienced a PHVL at day 7.Trial RegistrationClinicalTrials.gov identifier, NCT04634409.
Source: Infectious Diseases and Therapy - Category: Infectious Diseases Source Type: research